Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy

被引:0
|
作者
Côté, HCF
Magil, AB
Harris, M
Scarth, BJ
Gadawski, I
Wang, N
Yu, E
Yip, B
Zalunardo, N
Werb, R
Hogg, R
Harrigan, PR
Montaner, JS
机构
[1] British Columbia Ctr Excellence HIV AIDS, Providence Hlth Care, Vancouver, BC, Canada
[2] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada
[3] St Pauls Hosp, Providence Hlth Care, Vancouver, BC V6Z 1Y6, Canada
[4] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Tenofovir (TDF) exposure has been associated with renal dysfunction. Mitochondrial nephrotoxicity was investigated as an underlying mechanism. Given the interaction between TDF and didanosine (ddl), their concurrent use was also investigated. Design: Relative kidney biopsy mitochondrial DNA (mtDNA) to nuclear DNA ratios were measured retrospectively. HIV+ individuals on TDIF within 6 months preceeding the biopsy (HIV+/TDF+, n=21) were compared to HIV+ individuals who never received TDIF (HIV+/TDF-, n=10) and to HIV uninfected controls (HIV-,n=22). Twelve of the HIV+/TDF+ individuals received concurrent dell, 10 of those once at unadjusted ddl dosage. Tubular mitochondria morphology was also examined by electron microscopy. Statistical analyses were done on log-transformed mtDNA/nDNA, using non-parametric tests. Results: Kidney mtDNA levels were different among the three groups (P=0.046). mtDNA ratios were lower in HIV+/TDF+ subjects (7.5 [2.0-12.1]) than in HIV- ones (114.3 [6.0-16.5], P=0.014), but not lower than HIV+/TDF- controls (6.4 [2.8-11.9], P=0.82). Among HIV+ subjects, there was a difference between TDF-, TDF+/ddl(-) and TDF+/ddl(+) (P=0.005), with concurrent TDF/ddl use associated with lower mtDNA (2.1 [1.9-5.5], n=12) than TDF+/ddl(-) (113.8 [7.5-16.4], n=9, P=0.003). No TDF-/ddl(+) biopsies were available. In regression analyses, only HIV infection (P=0.03), and TDF/ddl use (P=0.003) were associated with lower mtDNA. At the ultrastructural level, abnormal tubular mitochondria was more prevalent in HIV+/TDF+ biopsies than HIV+/TDF- and HIV- ones together (P < 0.001) but not more so in TDF+/ddl(+) biopsies than TDF+/ddl(-) ones (P=0.67). Conclusions: Renal dysfunction in this population may be mediated through mitochondrial rephrotoxicity that involves more than one drug and/or pathogenesis. Kidney mtDNA depletion was associated with HIV infection and concurrent TDF/ddl therapy but not TDIF use alone, while kidney ultrastructural mitochondrial abnormalities were seen with TDIF use. The interaction between TDIF and drill may be relevant in the kidney where both drugs are cleared. The clinical relevance of our findings needs to be evaluated given the current recommendation for reduced doses of dell when used in conjunction with TDF.
引用
收藏
页码:79 / 86
页数:8
相关论文
共 50 条
  • [31] Body composition in HIV-infected patients receiving highly active antiretroviral therapy
    Chitu-Tisu, Cristina Emilia
    Barbu, Ecaterina Constanta
    Lazar, Mihai
    Bojinca, Mihai
    Tudor, Ana-Maria
    Hristea, Adriana
    Abagiu, Adrian Octavian
    Ion, Daniela Adriana
    Badarau, Anca Ioana
    [J]. ACTA CLINICA BELGICA, 2017, 72 (01) : 55 - 62
  • [32] Incidence of pneumonia in HIV-infected patients in the highly active antiretroviral therapy era
    Velasco Arribas, Maria
    Satue Bartolome, Jose Angel
    Losa Garcia, Juan Emilio
    Espinosa Gimeno, Alfredo
    Delgado-Iribarren, Alberto
    Castilla Castellano, Virgilio
    [J]. MEDICINA CLINICA, 2007, 128 (04): : 130 - 132
  • [33] Effect of Highly Active Antiretroviral Therapy on Hospitalization Characteristics of HIV-Infected Patients
    R. Nuesch
    N. Geigy
    E. Schaedler
    M. Battegay
    [J]. European Journal of Clinical Microbiology and Infectious Diseases , 2002, 21 : 684 - 687
  • [34] Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy
    Risa, KJ
    Nepon, L
    Justis, JC
    Panwalker, A
    Berman, SM
    Cinti, S
    Wagener, MM
    Singh, N
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2002, 13 (10) : 706 - 713
  • [35] Appendicitis in HIV-infected patients during the era of highly active antiretroviral therapy
    Crum-Cianflone, N.
    Weekes, J.
    Bavaro, M.
    [J]. HIV MEDICINE, 2008, 9 (06) : 421 - 426
  • [36] Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy
    Sevastianova, K
    Sutinen, J
    Westerbacka, J
    Ristola, M
    Yki-Järvinen, H
    [J]. ANTIVIRAL THERAPY, 2005, 10 (08) : 925 - 935
  • [37] Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients
    de Olalla, PG
    Knobel, H
    Carmona, A
    Guelar, A
    López-Colomés, JL
    Caylà, JA
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 30 (01) : 105 - 110
  • [38] Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
    Corona, Alberto
    Raimondi, Ferdinando
    [J]. CURRENT HIV RESEARCH, 2009, 7 (06) : 569 - 579
  • [39] HIV-infected patients' adherence to highly active antiretroviral therapy: A phenomenological study
    Mohammadpour, Ali
    Yekta, Zohre Parsa
    Nasrabadi, Ali R. Nikbakht
    [J]. NURSING & HEALTH SCIENCES, 2010, 12 (04) : 464 - 469
  • [40] Influence of highly active antiretroviral therapy on micronutrient profiles in HIV-infected patients
    Rousseau, MC
    Molines, C
    Moreau, J
    Delmont, J
    [J]. ANNALS OF NUTRITION AND METABOLISM, 2000, 44 (5-6) : 212 - 216